Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. It has licensed ALXN-1840, a candidate for the treatment of Wilson disease that was previously considered promising enough that Alexion, now an AZ subsidiary, paid $855 million to acquire it six years ago.